Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm(3): Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial

Lignende værker

• No Neurocognitive Advantage for Immediate Antiretroviral Treatment in adults with greater than 500 CD4+ T Cell Counts
  af: Wright, Edwina J, et al.
  Udgivet: (2018)
• Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial
  af: Baker, Jason V., et al.
  Udgivet: (2016)
• Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts >500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment trial
  af: KUNISAKI, Ken M., et al.
  Udgivet: (2015)
• CD4 Variability in Malawi: Implications for Use of a CD4 Threshold of 500 Cells/mm(3) Versus Universal Eligibility for Antiretroviral Therapy
  af: Schooley, Alan L., et al.
  Udgivet: (2016)
• Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment trial
  af: Sharma, S, et al.
  Udgivet: (2015)